Evidence map›Paper›PMID 36165292›Full record

ReviewCell transplantation

Diversified Treatment Options of Adult Stem Cells for Optic Neuropathies.

Shaoying Tan, Yao Yao, Qichen Yang, Xiang-Ling Yuan, Ling-Ping Cen, Tsz Kin Ng

Abstract readReview
In one paragraph

Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Unlocking the code for stroke treatment and care.Journal of central nervous system disease · 2024
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shaoying TanJoint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, China.
Yao YaoJoint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, China.
Qichen YangDepartment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.
Xiang-Ling YuanJoint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, China.
Ling-Ping CenJoint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, China.
Tsz Kin NgJoint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou, China.ORCID 0000-0001-7863-7229

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optic neuropathies refer to a group of ocular disorders with abnormalities or dysfunction of the optic nerve, sharing a common pathophysiology of retinal ganglion cell (RGC) death and axonal loss. RGCs, as the retinal neurons in the central nervous system, show limited capacity in regeneration or recovery upon diseases or after injuries. Critically, there is still no effective clinical treatment to cure most types of optic neuropathies. Recently, stem cell therapy was proposed as a potential treatment strategy for optic neuropathies. Adult stem cells, including mesenchymal stem cells and hematopoietic stem cells, have been applied in clinical trials based on their neuroprotective properties. In this article, the applications of adult stem cells on different types of optic neuropathies and the related mechanisms will be reviewed. Research updates on the strategies to enhance the neuroprotective effects of human adult stem cells will be summarized. This review article aims to enlighten the research scientists on the diversified functions of adult stem cells and consideration of adult stem cells as a potential treatment for optic neuropathies in future clinical practices.

Indexed as

Adult Stem CellsNeuroprotective AgentsOptic Nerve DiseasesOptic Nerve InjuriesHumansOptic NerveRetinal Ganglion CellsNeuroprotective Agentsadult stem cellsneuronal differentiationneuroprotectionoptic neuropathiesretinal ganglion cells

Identifiers

PMID36165292
PMCPMC9523835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.